Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Treatment begins in pivotal program for LX-211 in uveitis

Feb. 22, 2007

Inspire to commercialize AzaSite in U.S. and Canada

Feb. 20, 2007

AzaSite Plus well tolerated in phase I study

Feb. 15, 2007

Once-daily Xibrom formulation effective in treating postoperative ocular pain

Feb. 13, 2007

Thymosin beta 4 modulates NF-kB inflammatory signaling in corneal epithelium

Feb. 13, 2007

New therapeutic agents for glaucoma disclosed in recent Aerie patent

Feb. 8, 2007

RTP-801i for wet AMD begins phase I study

Feb. 6, 2007

CF-101 studied for dry eye syndrome in new phase II study

Feb. 6, 2007

ATG-3 completes phase I study for wet AMD

Feb. 2, 2007

Recent Dainippon Sumitomo patent discloses novel treatment option for glaucoma

Feb. 2, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...